Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies

Minno, Matteo Nicola Dario Di; Ambrosino, Pasquale; Lupoli, Roberta; Minno, Alessandro Di; Tasso, Marco; Peluso, Rosario; Tremoli, Elena

doi:10.3109/07853890.2015.1031822

Cited by 52 publications

(37 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This principle now mentions the importance of considering comorbidities, which are frequent in PsA and need to be assessed and treated. In particular, cardiovascular diseases and metabolic syndrome appear more common in patients with PsA than in controls 18 19…”

Section: Resultsmentioning

confidence: 99%

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

et al. 2015

View full text Add to dashboard Cite

BackgroundSince the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations.MethodsA systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated.ResultsThe updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used.ConclusionsThese recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.

show abstract

Section: Resultsmentioning

confidence: 99%

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…There is also an increased prevalence of subclinical atherosclerosis in patients with PsA 14 15. A recent meta-analysis confirmed an increased carotid intima-media thickness (IMT) (mean difference: 0.07 mm, p<0.001) and a higher frequency of carotid plaques (OR: 3.12, p=0.04) 15. Carotid atherosclerosis has been shown to improve risk prediction for incident CVD over what was achieved by a model with Framingham risk factors alone in the general population,16 as well as improving CV risk stratification in patients with PsA 14 17.…”

Section: Introductionmentioning

confidence: 99%

Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease

et al. 2017

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…Patients with PsA have an increased risk of subclinical atherosclerosis910. A recent meta-analysis revealed that PsA patients had an higher frequency of having carotid plaque compared with healthy controls [odds ratio (OR): 3.12]10. Although studies on the areal BMD (aBMD) by dual-energy X-ray absorptiometry (DXA) yielded conflicting results111213, two recent studies evaluated the bone quality of distal radius using high-resolution peripheral quantitative computed tomography (HR-pQCT) and found compromised volumetric BMD (vBMD) and microstructure in PsA patients1415.…”

mentioning

confidence: 99%

Carotid plaque and bone density and microarchitecture in psoriatic arthritis: the correlation with soluble ST2

Shen

Shang

Wong

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) patients have increased risk of both atherosclerosis and osteoporosis. Previous studies revealed that IL-33/ST2 axis may be related to both conditions; however, these associations were never evaluated in a single patients’ group. Here we explored the association among plasma levels of IL-33 and its decoy receptor soluble ST2 (sST2), carotid plaque determined by ultrasound, and volumetric bone mineral density (vBMD)/microstructure of distal radius measured by high-resolution peripheral quantitative computed tomography (HR-pQCT) in 80 PsA patients (55% male; 53.0 ± 10.1 years). Plasma sST2 levels were significantly higher in 33 (41%) patients with carotid plaques (11.2 ± 4.5 vs 7.7 ± 3.7 ng/ml, P < 0.001). In multivariate analysis, sST2 was an independent explanatory variable associated with carotid plaques (OR = 1.296, 95% CI: [1.091,1.540]; P = 0.003). After adjustment for the osteoporotic risk factors, sST2 was significantly associated with higher cortical porosity (β = 0.184, [0.042,0.325]; P = 0.012) and cortical pore volume (2.247, [0.434,4.060]; P = 0.016); and had a trend to be associated with lower cortical vBMD (−2.918, [−6.111,0.275]; P = 0.073). IL-33 was not associated with carotid plaque or vBMD/microstructure. In conclusion, plasma sST2 levels were independently correlated with both carotid plaque and compromised cortical vBMD/microstructure in PsA patients. IL-33/ST2 axis may be a link between accelerated atherosclerosis and osteoporosis in PsA.

show abstract

Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies

Abstract: These findings could help to establish more specific CV prevention strategies in this clinical setting.

Cited by 52 publications

References 47 publications

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease

Carotid plaque and bone density and microarchitecture in psoriatic arthritis: the correlation with soluble ST2

Contact Info

Product

Resources

About